Muscle-aging research
1Rodent muscle function and exercise adaptation.
MetabolicSmall molecule
5-Amino-1MQ
Nicotinamide N-methyltransferase (NNMT) inhibitor
Lab studiesMuscle aging1
Preclinical research chemical; not an FDA-approved treatment.
What does it do?
An experimental NNMT-inhibiting small molecule discussed for metabolism and aging; human benefits remain unestablished.
Approved & studied uses
Community uses Reported, unvalidated
Longevity
6Reference claims: NAD availability, mitochondrial function, repair, stress resistance.
Metabolism
6Energy, insulin sensitivity, glucose/fat fuel switching.
Weight management
6Fat oxidation, metabolic rate, body composition, appetite claims.
Reasons people report using it; these do not establish benefit.6
Evidence limits
View research →No human efficacy trial or human elimination half-life was verified.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Human safety is unresolved
The checked material does not establish a human adverse-event rate or safe self-use regimen for this exact product.2
Preclinical research chemical; not an FDA-approved treatment.
Molecular information
Amino-acid sequence
Not applicable: this compound is not a single peptide.
LengthNot a peptide sequence
Molecular weight · DaNot independently verified for the exact supplied form
Formula, sequence notation & identity
Molecular formulaNot independently verified for the exact supplied form1
Nicotinamide N-methyltransferase (NNMT) inhibitor
Salt, hydration, glycosylation and blend composition may change the supplied material; no unsupported formula or mass is assigned.
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life8 hours5
Route / formulationSource page: Oral. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 40 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Preclinical data only
Source’s reported peak time: 48 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Aged-mouse muscle findings
In aged sedentary mice, grip strength was approximately 40% higher with treatment; peak plantarflexor torque did not significantly change. These endpoints do not predict human strength gains.1
Reported timelines
Reference & communityOral: weeks 1–2 / 2–4 / 4–8 / 8–12
Reference sequence: energy/clarity; exercise/recovery; metabolic/body changes; longevity claims, unproven.6
Injection: weeks 1 / 2–3 / 3–4 / 4–6 / 6–8
Reported energy; metabolism; cardio breathlessness; body changes; plateau. Not validated.6
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 15 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 19 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 23 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 22 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 13 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 16 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “4007 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| OralOral (with food) | 25 mg | 1x daily | Conservative approachReference report | 8-12 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (with food) | 50 mgStarting dose | 1x daily | Standard starting doseReference report | 8-12 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (with food) | 75 mg | 1x daily | Typical maintenanceReference report | 8-12 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (with food) | 100 mg | 1x daily | Maximum doseReference report | 8-12 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (with meals) | 50 mg | 2x daily | Split dosing optionReference report | 8-12 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| SubQ | 2.5 mgStarting dose | 1x daily | Conservative starting dose (community Tier 4, PeptideDosages.com)Reference report | 4-8 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 5 mg | 1x daily | Standard community dose (community Tier 4, PeptideDosages.com)Reference report | 4-8 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| OtherNot tested | ~5 mg/kg/day (~350 mg for 70kg) | Theoretical | Human equivalent (FDA scaling)Reference report | 4-8 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Oral
- Use period
- 8-12 weeks
- Break
- 2-4 weeks off between cycles
Reported timing
With breakfast or lunch for better absorption
Injectable
- Use period
- 4-8 weeks
- Break
- 2-4 weeks off between cycles
Reported timing
Morning or early afternoon (avoid late day)
Animal and cell protocols 3
Laboratory exposures cannot establish a human dose.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 10 mg/kg | Daily | Muscle-function experimentAnimals | 8 weeks | 1 |
Population 22-month-old female mice Context The approximately seven-hour PK statement in this paper is animal data, not a human estimate. | |||||
| OralOral (HED only) | 50-100 mg | Theoretical | Oral allometric HED reference only (not a SubQ dose; derived from 10-20 mg/kg mouse SC data via FDA Km scaling)Reference report | 4-8 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQSubQ (mice) | 20 mg/kg TID (60 mg/kg/day) | 3x daily | Mouse study (PMC5826726)Reference report | 4-8 weeks | 6 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
No protocols match these filters.
Side effects & safety
Human safety is unresolved
The checked material does not establish a human adverse-event rate or safe self-use regimen for this exact product.
2Evidence
Animal findings do not validate human oral or injectable use.
Symptoms
Persistent nausea, headache, dizziness, weakness, insomnia, anxiety, palpitations, chest pain, rash, swelling, breathing difficulty, or injection infection need assessment.
Pregnancy
Safety unstudied in pregnancy/lactation.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Metformin
Caution reportedOverlapping metabolism.6
Reference report · Pep-Pedia label: Monitor CombinationBerberine
Caution reportedGlucose effects.6
Reference report · Pep-Pedia label: Monitor CombinationNMN / NR
Unverified pairingNAD precursor pairing.6
Reference report · Pep-Pedia label: SynergisticResveratrol
Unverified pairingSirtuin rationale.6
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingDifferent targets do not establish safety.6
Reference report · Pep-Pedia label: CompatibleBlood thinners
Unverified pairingNo established interaction data.6
Reference report · Evidence context: UnknownOther medicines and research compounds
Not establishedNo clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No universal bacteriostatic-water volume or validated preparation method is established for this entry.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Oral
The oral section describes capsules or measured powder, with food.
- Form
- Source describes a prepared product
- Reported parameters
- Storage: dry room-temperature conditions, protected from light and moisture.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Reported post-preparation interval: 28 days. · The source specifies refrigeration after preparation.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite to off-white capsulesReported appearanceThird-party testing certificatesReported appearanceProper pharmaceutical packagingReported concernMoisture damage or clumpingReported concernUnusual odor or appearance
6Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
6Cool, dry place at room temperature
Refrigerate 2-8°C, use within 28 days
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
PreclinicalCompound identity & other names
A small-molecule NNMT inhibitor investigated in rodent obesity and muscle-aging models. Human efficacy, dosing and pharmacokinetics are not established by the checked literature.
Preclinical research chemical; not an FDA-approved treatment.
How it may work
NNMT inhibition changes nicotinamide metabolism; proposed NAD-related effects require human confirmation.6
Aged-mouse muscle findings
In aged sedentary mice, grip strength was approximately 40% higher with treatment; peak plantarflexor torque did not significantly change. These endpoints do not predict human strength gains.
1Research areas and evidence gaps
Muscle-aging research. Rodent muscle function and exercise adaptation.1
- No human efficacy trial or human elimination half-life was verified.
- Research-market product identity, purity and formulation cannot be established from a publication.
Community reports Unvalidated
Metabolic discussions as described by Pep-Pedia.2
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
No additional 2025–2026 peer-reviewed efficacy trial of this exact product was identified in this targeted check. Earlier evidence and unresolved listed references are retained.
- Checked
- 2026-10-12
- Search
- 5-amino-1MQ NNMT 2025 2026 site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 3 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Muscle Function in Aged Mice (2024)Primary source checked
AI-PREPARED SUMMARY
Eight-week mouse experiment found higher grip strength with 5A-1MQ; it is not a human trial.
Aged-mouse muscle findings
In aged sedentary mice, grip strength was approximately 40% higher with treatment; peak plantarflexor torque did not significantly change. These endpoints do not predict human strength gains.
Pep-Pedia bibliography · Checked 2026-10-12
2Pep-Pedia: 5-Amino-1MQ — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
3Rat Pharmacokinetics Study (2021)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat oral bioavailability was reported as 38.4%, with half-lives of 6.9 hours orally and 3.8 hours intravenously.
Reported population / model
Animal PK study
Reported study details
Various doses · Bioavailability
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Mouse Obesity Study - Neelakantan et al. (2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Obese mice lost 5.1% body weight and had 30% smaller adipocytes. The source's human-equivalent calculation is not a tested human dose.
Reported population / model
Animal study
Reported study details
20mg/kg TID (60mg/kg/day) · 11 days · n=10 mice/group
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Pep-Pedia: 5-Amino-1MQ — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 8 hrs and a peak time of 48 min. Stated attribution: Preclinical data only. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
6Pep-Pedia: 5-Amino-1MQ — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12